Update of diagnosis and treatment of plasma cell leukemia
10.3760/cma.j.issn.1009-9921.2018.11.001
- VernacularTitle:浆细胞性白血病的诊治进展
- Author:
Yujun WEI
1
;
Zhongxia HUANG
Author Information
1. 100043,首都医科大学附属北京朝阳医院西院血液与肿瘤科
- Keywords:
Leukemia,plasma cell;
Hematopoietic stem cell transplantation;
Bortezomib;
Lenalidomide
- From:
Journal of Leukemia & Lymphoma
2018;27(11):641-644
- CountryChina
- Language:Chinese
-
Abstract:
Plasma cell leukemia (PCL) is a rare and aggressive malignant plasma cell tumor that is clinically susceptible to extramedullary lesions. It is classified into two types: primary PCL (pPCL) and secondary PCL (sPCL), of which 60 % are pPCL. The treatment of new drugs such as bortezomib and lenalidomide is important for improving the overall survival and disease-free survival of PCL, especially after induction of bortezomib-based chemotherapy,combined with autologous hematopoietic stem cell transplantation (auto-HSCT) can improve the survival of patients. Whether to adopt the next step of allogeneic hematopoietic stem cell transplantation (allo-HSCT) still needs further investigation. For young and suitable patients, early new drug-based regimen chemotherapy combined with auto-HSCT can be used, and if a suitable donor is available, the further allo-HSCT consolidation therapy is feasible. For elderly patients (≥65 years old), a new drug-based regimen can be used to induce chemotherapy, and further followed consolidation therapy plus maintenance therapy. Whether to take auto-HSCT after early induction chemotherapy depends on the individualized factors of the patient. The next generation anti-plasma cells drugs, monoclonal antibodies and other immunotherapies or new drugs in clinical trials are also worth exploring.
